Region Kronoberg

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease3 trials
• Metastatic breast cancer3 trials
• High blood pressure2 trials
• Type 2 diabetes2 trials
• Atrial fibrillation1 trial
• Bladder cancer1 trial
• Cervical cancer1 trial
• Gastric and oesophageal cancer1 trial
• Melanoma1 trial
• Pancreatic cancer1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 311 trials
• Phase 22 trials
• Phase 42 trials

Status

• Recruiting9 trials
• Active, not recruiting5 trials
• Completed1 trial

Lead sponsor

• AstraZeneca3 trials
• Karolinska University Hospital2 trials
• Lund University Hospital2 trials
• Uppsala University2 trials
• AstraZeneca AB1 trial
• and 5 more

Running trials

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

• Recruiting

  Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

  NCT06488482· Phase 3· Uppsala University· Source

• Recruiting

  A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer

  NCT05900206· Phase 2· Karolinska University Hospital· Source

• Recruiting

  SACK

  2022-501600-10-00· Phase 3· Karolinska University Hospital· Source

• Active, not recruiting

  Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast Cancer

  NCT04784714· Phase 3· AstraZeneca AB· Source

• Active, not recruiting

  Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

  NCT04862663· Phase 3· AstraZeneca· Source

• Recruiting

  Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

  NCT04910802· Phase 4· Miriam Elfström· Source

• Active, not recruiting

  Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial)

  2023-504945-30-00· Phase 3· Region Skane· Source

• Active, not recruiting

  NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

  NCT04335669· Phase 3· Lund University Hospital· Source

• Recruiting

  ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

  NCT03903835· Phase 3· Karolinska Institutet· Source

• Active, not recruiting

  Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.

  NCT03773367· Phase 2· Lund University Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease3 recruiting
• High blood pressure2 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

  NCT03982381· Phase 4· Uppsala University· Source